Vesalius Therapeutics, a company focused on delivering breakthrough treatments for common diseases and creating a platform to do so has entered a partnership with GSK aimed at the discovery and development of novel treatments for Parkinson’s Disease, as well as for another neurodegenerative condition.

Vesalius will leverage its platform to identify novel intervention points in Parkinson’s disease and one additional indication in neurodegeneration, whilst GSK will have the option to advance programmes against those novel intervention points. GSK will also gain global development and commercial rights from Vesalius to a preclinical small molecule programme with an initial focus in Parkinson’s disease.

GSK will control all development and commercialisation, whilst Vesalius will receive $80 million in upfront and equity payments, and is eligible to receive potential preclinical, development and commercial milestone payments of up to $570 million along with tiered royalties for the preclinical small molecule programme.